An Investigational Immuno-therapy Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Solid Cancers That Are Advanced or Have Spread

The purpose of this study is to evaluate the safety and effectiveness of experimental medication BMS-986207 by itself, in combination with Nivolumab, and in combination with both nivolumab and ipilimumab in participants with solid cancers that are advanced or have spread.

Inclusion Criteria

• Participant must consent for pretreatment and on treatment tumor biopsy samples
• For Part 1C tumor biopsies are optional
• Nonsmall cell lung cancer (NSCLC) without prior treatment in the advanced or metastatic setting (Part 2C)
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Must have received, and progressed or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting (Part 1A, 1B and 1C)
• Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria; radiographic tumor assessment performed within 28 days before randomization

Exclusion Criteria

• Primary central nervous system (CNS) disease, or tumors with CNS metastases as the only site of disease. Controlled brain metastases will be allowed to enroll
• Other active malignancy requiring concurrent intervention
• Uncontrolled/significant heart disease
• History of chronic hepatitis [except for hepatocellular carcinoma (HCC)]
• Active, known, or suspected autoimmune disease

Trial Phase Phase I/II

Trial Type Treatment

Lead Organization
Bristol-Myers Squibb

• Primary ID CA020-002
• Secondary IDs NCI-2017-00261, 2016-002263-34
• Clinicaltrials.gov ID NCT02913313